Genetic variant near cytosolic phospholipase A2 associated with schizophrenia

Craig J. Hudson, James L. Kennedy*, Andrew Gotowiec, Anna Lin, Nicole King, Katherine Gojtan, Fabio Macciardi, Karl Skorecki, Herbert Y. Meltzer, Jerry J. Warsh, David F. Horrobin

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

75 Scopus citations


Two studies were undertaken to determine a possible genetic basis for alterations in phospholipid metabolism in schizophrenia. Initial results demonstrated an association in 65 schizophrenics compared with a matched normal control population. A follow-up haplotype relative risk study of 44 triads (mother, father, affected offspring), confirmed the results seen in the association study. Results suggest that a genetic variant near the promotor region of the gene for cytosolic phospholipase A2, the rate-limiting enzyme in the synthesis of prostaglandins from arachidonic acid, is associated with schizophrenia.

Original languageEnglish (US)
Pages (from-to)111-116
Number of pages6
JournalSchizophrenia Research
Issue number2
StatePublished - Aug 23 1996


  • Genetic association
  • Genetic polymorphism
  • Haplotype relative risk
  • Phospholipase A
  • Schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry


Dive into the research topics of 'Genetic variant near cytosolic phospholipase A2 associated with schizophrenia'. Together they form a unique fingerprint.

Cite this